ERBB2 and breast cancer: In HER2+ BC dimerization most commonly occurs between the HER2 and HER3 receptors (Figure 1); HER3 can functionally bind ligands but is a catalytically dysfunctional tyrosine kinase so it acts primarily as an allosteric activator of the other family members [132–134].